Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort

BACKGROUND: Given the uncertainties inherent in clinical measures of prostate cancer aggressiveness, clinically validated tissue biomarkers are needed. We tested whether Alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) protein levels, measured by immunohistochemistry, and RNA expression, by RNA in situ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate
Autors principals: Brooks, James D., Wei, Wei, Pollack, Jonathan R., West, Robert B., Shin, Jun Ho, Sunwoo, John B., Hawley, Sarah J., Auman, Heidi, Newcomb, Lisa F., Simko, Jeff, Hurtado-Coll, Antonio, Troyer, Dean A., Carroll, Peter R., Gleave, Martin E., Lin, Daniel W., Nelson, Peter S., Thompson, Ian M., True, Lawrence D., McKenney, Jesse K., Feng, Ziding, Fazli, Ladan
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557496/
https://ncbi.nlm.nih.gov/pubmed/27325561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23225
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars